These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31913228)

  • 1. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
    Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
    Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
    Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
    Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
    Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
    Archer DF; Bernick BA; Mirkin S
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
    [No Abstract]   [Full Text] [Related]  

  • 6. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
    Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
    Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
    Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
    Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
    Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
    Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
    Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
    [No Abstract]   [Full Text] [Related]  

  • 11. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
    Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.
    Woodis CB; Ghassemi E; McLendon AN
    Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
    Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
    Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.
    Liu JH; Black DR; Larkin L; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Dec; 27(12):1388-1395. PubMed ID: 32842052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women.
    Sriprasert I; Mert M; Mack WJ; Hodis HN; Shoupe D
    Maturitas; 2021 Dec; 154():13-19. PubMed ID: 34736575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
    Shulman LP; Yankov V; Uhl K
    Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
    Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
    Rowan JP; Simon JA; Speroff L; Ellman H
    Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate/17β-estradiol and drospirenone/ethinyl estradiol on bleeding patterns in healthy women.
    Mansour D; Westhoff C; Kher U; Korver T
    Contraception; 2017 Apr; 95(4):390-397. PubMed ID: 28011288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Suckling J; Barlow D; Farquhar CM; Jepson RG; Roberts H
    Cochrane Database Syst Rev; 2004; (3):CD000402. PubMed ID: 15266429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.